Physician
Hematology
Suhail M. Ali, MB
|
|
Give Review
Suhail M. Ali, MB is an expert in the field of Hematology. He researched medicine at New York Medical College. Suhail M. Ali, MB is a published doctor and has 20 publications published. The lastest was: 'Antiresorptive therapy in the management of cancer treatment-induced bone loss.'
Publications
- Antiresorptive therapy in the management of Cancer treatment-induced bone loss.
- Circulating interleukin-8 levels explain breast Cancer osteolysis in mice and humans.
- Elevation in Multiple Serum Inflammatory Biomarkers Predicts Survival of Pancreatic Cancer Patients with Inoperable Disease.
- HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast Cancer.
- Identification of PTHrP(12-48) as a Plasma Biomarker Associated with Breast Cancer Bone Metastasis.
- Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapy.
- Impact of genetic targets on prostate Cancer therapy.
- Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14.
- Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic bre...
- Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate Cancer patients.
- Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast Cancer patients.
- Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and des...
- Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast Cancer.
- Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast Cancer.
- Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast Cancer.
- Serum HER-2/neu conversion to positive at the time of disease progression in patients with Breast carcinoma on hormone therapy.
- Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast Cancer.
- Serum osteoprotegerin levels in healthy controls and Cancer patients.
- Would screening for lung Cancer benefit 75- to 84-year-old residents of the United States?
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna
- CHAMPVA
- Cigna
- Commercial Insurance Company
- Coventry Health Care
- Geisinger Health Plan
- GEHA
- Mail Handlers Benefit Plan (MHBP)
- Medicare MCR
- Mutual of Omaha
- United Healthcare
Education
-
Geisinger Health System -
Washington University - Barnes-Jewish Hospital -
Henry Ford Hospital - Wayne State University -
New York Medical College -
Dow Medical College
Helpful Reviews
Similar Doctors
|
|
Dr. Karla M. Ludwig, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ruben Perez, MD
This Doctor is OpenDoctor Recommended.
|